XML 37 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The following table presents the notional contract amounts for forward contracts outstanding:

As of
FASB ASC Topic 815 DesignationSeptember 30, 2025December 31, 2024
Forward exchange contractsCash flow hedge$236,095 $224,177 
Forward exchange contractsNon-designated47,212 38,892 
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income and our consolidated condensed balance sheets:

Amount of Gain (Loss) Recognized in AOCI
Consolidated Condensed Statements of Comprehensive Income
Amount of Gain (Loss) Reclassified from AOCI
Three Months Ended September 30,
Total Amount of Line Item Presented
Derivative Instrument20252024Location of amount reclassified2025202420252024
Foreign exchange contracts$4,387 $(9,073)Net Sales$337,926 $316,701 $(653)$270 
 Cost of Sales171,807 137,706 112 (2)
Pre-tax gain (loss)
$4,387 $(9,073)$(541)$268 
Tax expense (benefit)
1,063 (2,199)(131)65 
Net gain (loss)
$3,324 $(6,874)$(410)$203 

Amount of Loss Recognized in AOCI
Consolidated Condensed Statements of Comprehensive Income
Amount of Gain (Loss) Reclassified from AOCI
Nine Months Ended September 30,
Total Amount of Line Item Presented
Derivative Instrument20252024Location of amount reclassified2025202420252024
Foreign exchange contracts$(9,219)$(2,314)Net Sales$1,001,526 $961,071 $505 $2,260 
Cost of Sales469,336 426,383 (781)1,370 
Pre-tax gain (loss)
$(9,219)$(2,314)$(276)$3,630 
Tax expense (benefit)
(2,235)(560)(67)880 
Net gain (loss)
$(6,984)$(1,754)$(209)$2,750 
Derivatives Not Designated as Hedging Instruments
Net losses from derivative instruments not accounted for as hedges and gains (losses) on our intercompany receivables on our consolidated condensed statements of comprehensive income were:

Three Months Ended September 30,Nine Months Ended September 30,
Derivative Instrument
Location on Consolidated Condensed Statements of Comprehensive Income
2025202420252024
  
Net loss on currency forward contracts
Selling and administrative expense$(150)$(1,513)$(2,230)$(631)
Net gain (loss) on currency transaction exposures
Selling and administrative expense$(690)$1,108 $653 $(1,102)
Schedule of Fair Value for Forward Foreign Exchange Contracts The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2025 and December 31, 2024:
September 30, 2025Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:   
Foreign exchange contractsOther current liabilities$2,636 $(5,290)$(2,654)
Foreign exchange contracts
Other long-term liabilities
586 (1,203)(617)
$3,222 $(6,493)$(3,271)
Derivatives not designated as hedging instruments:   
Foreign exchange contractsOther current liabilities1 (230)(229)
Total derivatives$3,223 $(6,723)$(3,500)

December 31, 2024Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:  
Foreign exchange contracts Prepaid expenses and other current assets$8,702 $(3,294)$5,408 
Foreign exchange contracts
Other assets
388 (124)264 
$9,090 $(3,418)$5,672 
Derivatives not designated as hedging instruments:  
Foreign exchange contractsOther current liabilities33 (110)(77)
Total derivatives$9,123 $(3,528)$5,595 
Fair Value Measurement Inputs and Valuation Techniques The recurring Level 3 fair value measurements of contingent consideration for which the liabilities are recorded include the following significant unobservable inputs as of September 30, 2025:
Assumptions
Unobservable InputIn2BonesBiorez
Discount rate7.13%12.16%
Revenue volatility17.47%20.83%
Projected year of payment
2025-2026
2025-2026
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Changes in the fair value of contingent consideration liabilities for the nine months ended September 30, 2025 and 2024 are as follows:
In2BonesBiorez
2025202420252024
Balance as of January 1,$11,196 $41,393 $61,021 $128,751 
Payments
— (3,028)(22,577)(45,056)
Changes in fair value of contingent consideration(8,828)(27,269)12,332 (14,999)
Balance as of September 30,$2,368 $11,096 $50,776 $68,696